Market research
IDRA Idera Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 1.3
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- 0.0%
- Beta
- 1.3
About
About Idera Pharmaceuticals Inc
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Research context
Idera Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IDRA discussion.
5 years, 7 months ago
Idera Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 61.7% below its 200 day moving average.
From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 42.1.
Idera Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 230.2% to $-77M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.7% to $-8M since the same quarter in the previous year.
Based on the above factors, Idera Pharmaceuticals, Inc gets an overall score of 2/5.